Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma

NCT07712757 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

140

Enrollment

INDUSTRY

Sponsor class

Conditions

Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation
Astrocytoma IDH Mutant Grade 2
Oligodendroglioma
Oligodendroglioma IDH-mutant and 1p/19q-codeleted
IDH-mutant Gliomas

Interventions

DRUG: Safusidenib
DRUG: Placebo

Sponsor

Nuvation Bio Inc.